Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021)

Reich K.; Papp K. A.; Blauvelt A.

首页> 外文期刊>The Lancet >Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021)

【24h】

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021)

机译：Bimekizumab与Ustekinumab用于治疗中度至重度斑块的牛皮癣（生动）：52周，多方面，双盲，活跃的比较器和安慰剂控制第3阶段试验的功效和安全性（Vol 397，PG 487,2021）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2021年第10275期|共1页
作者
Reich K.; Papp K. A.; Blauvelt A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind,placebo-controlled multicenter trial [J] . YANG Hai-zhen, LIU Xiao-ming, TU Cai-xia, 中华医学杂志（英文版） . 2012,第011期
2. A double-blind,randomized,placebo- and positive-controlled phase Ⅲ trial of 1％ benvitimod cream in mild-to-moderate plaque psoriasis [J] . Lin Cai, Sen Yang, Fu-Qiu Li, 中华医学杂志（英文版） . 2020,第024期
3. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial [J] . Reich Kristian, Papp Kim A., Blauvelt Andrew, The Lancet . 2021,第10273期

机译：Bimekizumab与Ustekinumab用于治疗中度至重度斑块的牛皮癣（生动）：52周，多期，双盲，活跃比较器和安慰剂控制第3阶段试验的功效和安全性
4. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY):a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial (vol 397, pg 475, 2021) [J] . Gordon K. B., Foley P., Krueger J. G. The Lancet . 2021,第10280期

机译：Bimekizumab疗效和安全性中度至重度斑块牛皮癣（准备好）：多期，双盲，安慰剂控制，随机撤离第3阶段试验（第397 Vol 397，PG 475,2021）
5. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [J] . Gordon Kenneth B., Foley Peter, Krueger James G., The Lancet . 2021,第10273期

机译：Bimekizumab疗效和安全性中度至重度斑块的牛皮癣（准备就绪）：多期，双盲，安慰剂控制，随机戒断第3阶段试验
6. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3 double-blind randomized placebo-controlled study-(PURSUIT-J study) [O] . Toshifumi Hibi, Yuya Imai, Asako Senoo, -1

机译：Golimumab 52周维持疗法对日本中度至重度活动性溃疡性结肠炎患者的疗效和安全性：一项三期双盲随机安慰剂对照研究-（PURSUIT-J研究）
7. Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) [O] . RB Warren, A Blauvelt, J Bagel, 2021

机译：Bimekizumab疗效和安全性与中度至重度斑块牛皮癣患者的疗效和安全性：由多中心，随机，双盲有效的比较器控制相3试验的结果（可以确定）

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (vol 397, pg 487, 2021)

著录项

相似文献

相关主题

期刊订阅